{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:03:15Z","timestamp":1787241795472,"version":"build-2736575974"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.2169\/internalmedicine.1553-18","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T18:24:38Z","timestamp":1536690278000},"page":"345-353","source":"Crossref","is-referenced-by-count":10,"title":["The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry"],"prefix":"10.2169","volume":"58","author":[{"given":"Daisuke","family":"Ueshima","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yamate Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Sasaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[{"name":"Sakakibara Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ashikaga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504, 2004.","DOI":"10.1056\/NEJMoa040583"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718, 2001.","DOI":"10.1001\/jama.285.13.1711"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387-2397, 2015.","DOI":"10.1056\/NEJMoa1410489"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129 (Suppl): S76-S99, 2014.","DOI":"10.1161\/01.cir.0000437740.48606.d1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33: 1635-1701, 2012.","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"6","unstructured":"6. Sorlie PD, Feinleib M. The serum cholesterol-cancer relationship: an analysis of time trends in the Framingham Study. J Natl Cancer Inst 69: 989-996, 1982."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the multiple risk factor intervention trial. JAMA 257: 943-948, 1987.","DOI":"10.1001\/jama.257.7.943"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50: 409-418, 2007.","DOI":"10.1016\/j.jacc.2007.02.073"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fruchter O, Yigla M, Kramer MR. Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease. Am J Med Sci 349: 338-343, 2015.","DOI":"10.1097\/MAJ.0000000000000435"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70: 482-487, 2011.","DOI":"10.1136\/ard.2010.135871"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Perez-Baos S, Barrasa JI, Gratal P, et al. Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. Br J Pharmacol 174: 3018-3031, 2017 (Epub ahead of print).","DOI":"10.1111\/bph.13932"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Reddy VS, Bui QT, Jacobs JR, et al. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol 115: 557-562, 2015.","DOI":"10.1016\/j.amjcard.2014.12.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang TY, Newby LK, Chen AY, et al. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clin Cardiol 32: E22-E28, 2009.","DOI":"10.1002\/clc.20518"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cheng KH, Chu CS, Lin TH, Lee KT, Sheu SH, Lai WT. Lipid paradox in acute myocardial infarction-the association with 30-day in-hospital mortality. Crit Care Med 43: 1255-1264, 2015.","DOI":"10.1097\/CCM.0000000000000946"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki prefectural health study. Circulation 119: 2136-2145, 2009.","DOI":"10.1161\/CIRCULATIONAHA.108.795666"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320: 904-910, 1989.","DOI":"10.1056\/NEJM198904063201405"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 2155-2166, 2014.","DOI":"10.1056\/NEJMoa1409312"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381: 1107-1115, 2013.","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 127: 634-640, 2013.","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Konishi Y, Ashikaga T, Sasaoka T, Kurihara K, Yoshikawa S, Isobe M. Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study. J Cardiol 67: 241-247, 2016.","DOI":"10.1016\/j.jjcc.2015.05.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ueshima D, Ashikaga T, Yoshikawa S, et al. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: the landmark analysis from Tokyo-MD PCI registry. J Cardiol 69: 815-822, 2017.","DOI":"10.1016\/j.jjcc.2016.08.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kurihara K, Ashikaga T, Sasaoka T, Yoshikawa S, Isobe M; Tokyo MDPCISI. Incidence and predictors of early and late target lesion revascularization after everolimus-eluting stent implantation in unselected patients in japan. Catheter Cardiovasc Interv 90: 78-86, 2017.","DOI":"10.1002\/ccd.26964"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. D&apos;Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281, 1998.","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 308: 373-379, 1994.","DOI":"10.1136\/bmj.308.6925.373"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA 273: 1926-1932, 1995.","DOI":"10.1001\/jama.273.24.1926"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation 92: 2396-2403, 1995.","DOI":"10.1161\/01.CIR.92.9.2396"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-M156, 2001.","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol 103: 1616-1621, 2009.","DOI":"10.1016\/j.amjcard.2009.01.375"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ramsay SE, Arianayagam DS, Whincup PH, et al. Cardiovascular risk profile and frailty in a population-based study of older British men. Heart 101: 616-622, 2015.","DOI":"10.1136\/heartjnl-2014-306472"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ranieri P, Rozzini R, Franzoni S, Barbisoni P, Trabucchi M. Serum cholesterol levels as a measure of frailty in elderly patients. Exp Aging Res 24: 169-179, 1998.","DOI":"10.1080\/036107398244300"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 51: 1440-1445, 2008.","DOI":"10.1016\/j.jacc.2007.11.075"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22: 933-940, 1993.","DOI":"10.1016\/0735-1097(93)90213-K"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: 1093-1100, 2010.","DOI":"10.1378\/chest.10-0134"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315: 1735-1749, 2016.","DOI":"10.1001\/jama.2016.3775"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/3\/58_1553-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T00:33:58Z","timestamp":1549067638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/3\/58_1553-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1553-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}